Future Directions in ATTR-CM Treatment
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Future Directions in ATTR-CM Treatment
-
ナレーター：
-
著者：
In this CardiaCast episode, Kevin M. Alexander, MD is joined by Sarah Cuddy, MBBCh, to discuss the latest clinical data for investigational therapies and available treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential implications of these findings on clinical practice and future clinical studies. First, they will explore results from CARDIO-TTRansform, the phase 3 trial of eplontersen in ATTR-CM, followed by the results from REVEAL, the phase 3 trial using radiotracer I-124 evuzamitide to detect cardiac amyloidosis. Next, they will discuss findings from ATTRibute-CM and its open-label extension on the survival benefits of acoramidis in variant ATTR-CM (ATTRv-CM) over 54 months. Lastly, they will cover recently published studies describing the extracardiac effects of available therapies for ATTR-CM, specifically those describing the effects of acoramidis on kidney function and the effects of vutrisiran on gastrointestinal events.
This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology.